2024-11-1020171080-768310.1089/jop.2016.00972-s2.0-85018256991http://dx.doi.org/10.1089/jop.2016.0097https://hdl.handle.net/20.500.14288/16065Purpose: To report the efficacy and safety of interferon (IFN) alpha-2a in patients with cystoid macular edema (CME) associated with presumed ocular tuberculosis (TB). Methods: We reviewed the clinical records of 5 patients with presumed ocular TB who had been treated with IFN alpha-2a for recurrent CME during or after completion of anti-tubercular therapy. IFN alpha-2a was administered at an initial dose of 3 million IU per day and then tapered after the initial response. Treatment efficacy was assessed by central macular thickness (CMT) measurement using spectral-domain optical coherence tomography and visual acuity. Results: Three patients were men, and 2 were women. Patients were aged between 38 and 66 years. Mean CMT was 483 +/- 178.6 mm at baseline, 302.3 +/- 56 mm at 1 week, 312.3 +/- 49.5 mm at 1 month, and 286.2 +/- 31.9 mm at 3 months. Mean LogMAR visual acuity was 0.6 +/- 0.4 at baseline, 0.4 +/- 0.3 mm at 1 week, 0.3 +/- 0.3 at 1 month, and 0.3 +/- 0.3 at 3 months. The treatment was interrupted for 10 days because of neutropenia after 2 weeks in 1 patient and discontinued in another after 10 days because of intolerance. Total treatment duration was 3-24 months in the remaining 4 patients. Conclusion: The present small case series suggests that IFN alpha-2a may be an effective and safe therapeutic option for CME that is associated with presumed ocular TB.OphthalmologyPharmacologyPharmacyJournal Article1557-7732400185000014Q35969